- Home
- NIE vs TYRA Comparison
NIE vs TYRA Comparison
Compare NIE & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- TYRA
- Stock Information
- Founded
- NIE 2007
- TYRA 2018
- Country
- NIE United States
- TYRA United States
- Employees
- NIE N/A
- TYRA N/A
- Industry
- NIE Investment Managers
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- NIE Finance
- TYRA Health Care
- Exchange
- NIE Nasdaq
- TYRA Nasdaq
- Market Cap
- NIE 660.9M
- TYRA 576.6M
- IPO Year
- NIE N/A
- TYRA 2021
- Fundamental
- Price
- NIE $23.94
- TYRA $10.47
- Analyst Decision
- NIE
- TYRA Strong Buy
- Analyst Count
- NIE 0
- TYRA 7
- Target Price
- NIE N/A
- TYRA $30.86
- AVG Volume (30 Days)
- NIE 70.5K
- TYRA 364.1K
- Earning Date
- NIE 01-01-0001
- TYRA 08-06-2025
- Dividend Yield
- NIE 9.04%
- TYRA N/A
- EPS Growth
- NIE N/A
- TYRA N/A
- EPS
- NIE N/A
- TYRA N/A
- Revenue
- NIE N/A
- TYRA N/A
- Revenue This Year
- NIE N/A
- TYRA N/A
- Revenue Next Year
- NIE N/A
- TYRA N/A
- P/E Ratio
- NIE N/A
- TYRA N/A
- Revenue Growth
- NIE N/A
- TYRA N/A
- 52 Week Low
- NIE $18.61
- TYRA $6.42
- 52 Week High
- NIE $22.47
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- NIE 62.81
- TYRA 58.12
- Support Level
- NIE $23.71
- TYRA $9.93
- Resistance Level
- NIE $24.05
- TYRA $10.49
- Average True Range (ATR)
- NIE 0.26
- TYRA 0.59
- MACD
- NIE 0.02
- TYRA 0.08
- Stochastic Oscillator
- NIE 89.59
- TYRA 94.30
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.